Cochrane · systematic review · CD012548
Degarelix for treating advanced hormone‐sensitive prostate cancer
Zengerling, F, Jakob, JJ, Schmidt, S, et al. · Cochrane Database of Systematic Reviews · 2021 · Cochrane Library
UrologyAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
6
current version
GRADE rated
4
No studies
2
Included studies
NR
No studies 2 · 33.3%Ungraded 0 · 0%Very low 1 · 16.7%Low 1 · 16.7%Moderate 2 · 33.3%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Degarelix compared to standard androgen suppression therapy for treating advanced hormone‐sensitive prostate cancer
Population: hormone‐sensitive prostate cancer
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival Degarelix vs standard androgen suppression therapy | no estimate extracted | NR | No studies |
Serious adverse events Degarelix vs standard androgen suppression therapy | RR 0.8 [0.62, 1.05] | 9 studies · 2750 participants | Low Downgraded: risk of bias, imprecision |
Quality of life Degarelix vs standard androgen suppression therapy | no estimate extracted | 3 studies · 2887 participants | Moderate Downgraded: risk of bias |
Cancer‐specific survival  Degarelix vs standard androgen suppression therapy | no estimate extracted | NR | No studies |
Cardiovascular events Degarelix vs standard androgen suppression therapy | RR 0.15 [0.04, 0.61] | 1 study · 80 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Injection site pain Degarelix vs standard androgen suppression therapy | RR 15.68 [7.41, 33.17] | 8 studies · 2670 participants | Moderate Downgraded: risk of bias |